#livdelzi for #PBC efficacy highlights
✅ 62% met primary endpoint vs. unprecedented 20% placebo
🔥 25% normalized alkphos vs. 0% placebo
🔥 improvement in objective itch scales likely makes #seladelpar itch beneficial vs. itch neutral
#livertwitter...

More from the #livdelzi label

✅ 10 mg with or without food
✅ give 4 h away from resin if co ad
✅ 10% ⬇️ eGFR by 25% vs. 2% pbo (but returned to baseline with no rx or 🛑)
✅ rare ALT elevation >3xULN at 50-200 mg doses much higher than label
✅ 4% fractures vs. 0% pbo

Highlights of #livdelzi label include DDIs.

✅ avoid with OAT-3 inh (cabotegravir, rifampicin, probenecid)
✅ monitor if on rifampin, CSA
✅ avoid with strong CYP2C19 inh (fluvoxamine, carbamazepine, fluconazole)
🔥 no meaningful interactions with statins
#LiverTwitter

The full label for #livdelzi is linked below. #LiverTwitter

www.accessdata.fda.gov/drugsatfda_docs/label/20...

#seladelpar is now #livdelzi as it gains ⁦@US_FDA⁩ approval as second line therapy for #PBC
More great news for people living with this disease ⁦@PBCers⁩ ⁦@pbcercarol⁩ #livertwitter ...